The Utility of Galactomannan and Polymerase Chain Reaction Assays in Bronchoalveolar Lavage for Diagnosis of Chronic Pulmonary Aspergillosis

The diagnosis of chronic pulmonary aspergillosis (CPA) is established by combined clinic-radio-microbiological criteria. Out of the different microbiological criteria, a positive serology for Aspergillus -specific IgG levels is the cornerstone of diagnosis. Alternatively, other microbiological evide...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Mycopathologia (1975) 2023-12, Vol.188 (6), p.1041-1053
Hauptverfasser: Chowdhury, Mohit, Singh, Gagandeep, Pandey, Mragnayani, Mishra, Himanshu, Meena, Ved Prakash, Sethi, Prayas, Singh, Amandeep, Prakash, Bindu, Upadhyay, Ashish Datt, Mohan, Anant, Sinha, Sanjeev, Xess, Immaculata, Wig, Naveet, Kabra, Sushil Kumar, Ray, Animesh
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The diagnosis of chronic pulmonary aspergillosis (CPA) is established by combined clinic-radio-microbiological criteria. Out of the different microbiological criteria, a positive serology for Aspergillus -specific IgG levels is the cornerstone of diagnosis. Alternatively, other microbiological evidence are sometimes sought viz., positive Aspergillus antigen (broncho-alveolar lavage fluid, i.e., BALF galactomannan ≥ 1.0), histopathological demonstration of the fungi following lung biopsy or resection, demonstration of hyaline septate hyphae in direct microscopy resembling Aspergillus spp. or its growth on a respiratory specimen. However, the exact roles of BALF- GM and the newer BALF-PCR have not been confirmed by studies till date. This study enrolled 210 patients with suspected CPA. Of the participants, 88 patients met the criteria for CPA, whereas 122 patients had an alternative diagnosis. The sensitivity—specificity of AsperGenius® PCR and "in-house” PCR were 52.27(36.69–67.54) %—33.78 (23.19–45.72) % and 36.36 (22.41–52.23) %—39.19 (28.04–51.23) % respectively. The sensitivity/specificity of BALF (> 1.0) and serum galactomannan (> 1.0) were 46.55% (33.34–60.13)/64.08% (54.03–73.3) and 29.82% (22.05–37.6)/86.84% (81.1–92.59) respectively. The optimal cut-off values for BALF-Galactomannan and serum galactomannan in diagnosing CPA were found to be 0.69 (sensitivity: 64%; specificity: 53%) and 0.458 (sensitivity: 67%; specificity: 64%) respectively. This results of this study suggests that  Aspergillus PCR from BAL may not be a good “rule-in” test for diagnosing CPA. While the performances of GM in BAL and serum may be better than PCR, it should be best used in conjunction with other clinical, radiological, and other microbiological characteristics.
ISSN:0301-486X
1573-0832
DOI:10.1007/s11046-023-00797-z